Unison Pharmaceuticals Pvt. Ltd. Revenue and Competitors

Ahmedabad, India

Location

N/A

Total Funding

Industry

Employee Data

  • Unison Pharmaceuticals Pvt. Ltd. has 92 Employees.(i)
  • Unison Pharmaceuticals Pvt. Ltd. grew their employee count by 37% last year.

What Is Unison Pharmaceuticals Pvt. Ltd.?

With almost four decades of medical service to the society, Unison Pharmaceuticals is an emerging global pharmaceutical company with strong identity in Indian market (Gujarat) and started spreading the wings in regulated and semi-regulated markets. Our vision of becoming a globally renowned company is supported by dedicated team of R&D scientists, pharmacists and state-of-an-art manufacturing facilities equipped with latest technologies. Our philosophy is to provide world class quality medicines at most affordable price to ensure the best healthcare possible. With our core competence in chronic segments; Anti-Hypertensives, Anti-Diabetics and Lipid-Lowering drugs, we have more than 165 products in the basket with presence in different therapeutic segments like; Anti-hypertensives, Anti-Diabetics, Lipid-lowering, Anti-Infective, Anti-biotics, Respiratory management, Hematinics, Anti-Allergics, Steroids, Psychotropics, Calcium and Vitamin Supplements and others.

keywords:N/A

N/A

Total Funding

92

Number of Employees

N/A

Revenue (est)

37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Unison Pharmaceuticals Pvt. Ltd. News

2022-04-20 - Aluminum Bottle Market Size ndustry Share, Global Trend, In ...

... Cosme Packaging Co.,Ltd., Unison Kudos, Systunix Private Limited, ... Application (Food and Beverages, Healthcare and Pharmaceuticals,...

2022-04-19 - ??? ?? ??? 15 ????? ?? MRP ???? ??, ???? ??????? ??? ???? ???? ???? ??? ??, ????? ?????

M/s Synokem Pharmaceuticals Ltd. / M/s Apex Laboratories Private Limited. 10.70. 5. Dapagliflozin + Metformin Hydrochloride Extended release...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M928%N/A
#2
$11.3M923%N/A
#3
$9.2M926%N/A
#4
$4.4M94N/AN/A
#5
N/A9512%N/A